Wei Jie, Lane Nancy E, Bolster Marcy B, Dubreuil Maureen, Zeng Chao, Misra Devyani, Lu Na, Choi Hyon K, Lei Guanghua, Zhang Yuqing
Health Management Center, Xiangya Hospital, Central South University, Changsha, China.
Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
J Bone Miner Res. 2020 Apr;35(4):631-640. doi: 10.1002/jbmr.3935. Epub 2020 Feb 5.
Several professional organizations have recommended tramadol as one of the first-line or second-line therapies for patients with chronic noncancer pain and its prescription has been increasing rapidly worldwide; however, the safety profile of tramadol, such as risk of fracture, remains unclear. This study aimed to examine the association of tramadol with risk of hip fracture. Among individuals age 50 years or older without a history of hip fracture, cancer, or opioid use disorder in The Health Improvement Network (THIN) database in the United Kingdom general practice (2000-2017), five sequential propensity score-matched cohort studies were assembled, ie, participants who initiated tramadol or those who initiated one of the following medications: codeine (n = 146,956) (another commonly used weak opioid), naproxen (n = 115,109) or ibuprofen (n = 107,438) (commonly used nonselective nonsteroidal anti-inflammatory drugs [NSAIDs]), celecoxib (n = 43,130), or etoricoxib (n = 27,689) (cyclooxygenase-2 inhibitors). The outcome was incident hip fracture over 1 year. After propensity-score matching, the included participants had a mean age of 65.7 years and 56.9% were women. During the 1-year follow-up, 518 hip fracture (3.7/1000 person-years) occurred in the tramadol cohort and 401 (2.9/1000 person-years) occurred in the codeine cohort. Compared with codeine, hazard ratio (HR) of hip fracture for tramadol was 1.28 (95% confidence interval [CI] 1.13 to 1.46). Risk of hip fracture was also higher in the tramadol cohort than in the naproxen (2.9/1000 person-years for tramadol, 1.7/1000 person-years for naproxen; HR = 1.69, 95% CI 1.41 to 2.03), ibuprofen (3.4/1000 person-years for tramadol, 2.0/1000 person-years for ibuprofen; HR = 1.65, 95% CI 1.39 to 1.96), celecoxib (3.4/1000 person-years for tramadol, 1.8/1000 person-years for celecoxib; HR = 1.85, 95% CI 1.40 to 2.44), or etoricoxib (2.9/1000 person-years for tramadol, 1.5/1000 person-years for etoricoxib; HR = 1.96, 95% CI 1.34 to 2.87) cohort. In this population-based cohort study, the initiation of tramadol was associated with a higher risk of hip fracture than initiation of codeine and commonly used NSAIDs, suggesting a need to revisit several guidelines on tramadol use in clinical practice. © 2020 American Society for Bone and Mineral Research.
几个专业组织已推荐将曲马多作为慢性非癌性疼痛患者的一线或二线治疗药物之一,其处方量在全球范围内迅速增加;然而,曲马多的安全性,如骨折风险,仍不明确。本研究旨在探讨曲马多与髋部骨折风险之间的关联。在英国全科医疗健康改善网络(THIN)数据库中年龄50岁及以上且无髋部骨折、癌症或阿片类药物使用障碍病史的个体中(2000 - 2017年),进行了五项连续的倾向评分匹配队列研究,即开始使用曲马多的参与者或开始使用以下药物之一的参与者:可待因(n = 146,956)(另一种常用的弱阿片类药物)、萘普生(n = 115,109)或布洛芬(n = 107,438)(常用的非选择性非甾体抗炎药[NSAIDs])、塞来昔布(n = 43,130)或依托考昔(n = 27,689)(环氧化酶 - 2抑制剂)。结局指标为1年内发生的髋部骨折。倾向评分匹配后,纳入的参与者平均年龄为65.7岁,56.9%为女性。在1年的随访期间,曲马多队列中有518例髋部骨折(3.7/1000人年)发生,可待因队列中有401例(2.9/1000人年)发生。与可待因相比,曲马多导致髋部骨折的风险比(HR)为1.28(95%置信区间[CI] 1.13至1.46)。曲马多队列中髋部骨折的风险也高于萘普生队列(曲马多为2.9/1000人年,萘普生为1.7/1000人年;HR = 1.69,95% CI 1.41至2.03)、布洛芬队列(曲马多为3.4/1000人年,布洛芬为2.0/1000人年;HR = 1.65,95% CI 1.39至1.96)、塞来昔布队列(曲马多为3.4/1000人年,塞来昔布为1.8/1000人年;HR = 1.85,95% CI 1.40至2.44)或依托考昔队列(曲马多为2.9/1000人年,依托考昔为1.5/1000人年;HR = 1.96,95% CI 1.34至2.87)。在这项基于人群的队列研究中,开始使用曲马多与髋部骨折风险高于开始使用可待因和常用NSAIDs相关,提示有必要重新审视临床实践中关于曲马多使用的若干指南。© 2020美国骨与矿物质研究学会